HIF-PHIs May Offer Benefit over ESAs for Anemia With Dialysis-Dependent CKD
Jyoti Tyagi, MPH Credit: Linkedin Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) seem to be a feasible alternative to erythropoietin-stimulating agents (ESA) for treating anemia in people with dialysis-dependent chronic kidney disease (DD-CKD), according to a new systematic review and meta-analysis.1 Specifically, daprodustat exhibited a substantial net benefit over ESAs in reducing the need for intravenous … Read more